Intervacc is trading 17.02% down at €0.07; no confirmed company-specific catalyst was identified for August 18, 2026.
- The latest material developments were an EMA application seeking 12-month Strangvac immunity and a New Zealand shipment under special approval, both reported before the session decline.
- Major indices were flat, with no direct market catalyst identified.
- Q2 results are scheduled for August 20, 2026.